ATF4 and achalasia-alacrima syndrome: Our results demonstrate the PERK/eIF2α/ATF4 activity within VSMCs may be an attractive therapeutic target for AAAs, as it can prevent smooth muscle dysfunction and decrease pathological vascular remodeling.